Peginesatide acetate

Peginesatide acetate is a synthetic, peptide-based erythropoiesis stimulating agent (ESA). It was developed by Affymax and Takeda Pharmaceuticals for the treatment of anemia associated with chronic kidney disease (CKD). Peginesatide acetate is unique among ESAs because it is not a protein or glycoprotein, but a peptide that is covalently linked to polyethylene glycol (PEG).

Mechanism of Action

Peginesatide acetate works by stimulating the bone marrow to produce more red blood cells, thereby increasing the oxygen-carrying capacity of the blood. It binds to and activates the erythropoietin receptor on the surface of red blood cell precursors in the bone marrow, mimicking the action of the natural hormone erythropoietin.

Clinical Use

Peginesatide acetate was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of anemia due to CKD in adult patients on dialysis. However, it was withdrawn from the market in 2013 due to safety concerns related to severe hypersensitivity reactions.

Side Effects

Common side effects of peginesatide acetate include nausea, vomiting, diarrhea, and hypertension. Serious side effects can include severe allergic reactions, increased risk of stroke, and increased mortality in patients with CKD not on dialysis.

See Also

• Erythropoiesis stimulating agent
• Anemia
• Chronic kidney disease
• Affymax
• Takeda Pharmaceuticals